| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $6,658,093 | 12 | 100 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | 0 | $0 | 3 | $492,522 | $-492,522 |
| Nolan Sean P. | Chief Executive Officer | 0 | $0 | 2 | $840,196 | $-840,196 |
| Nagendran Sukumar | President and Head of R&D | 0 | $0 | 7 | $5.33M | $-5.33M |
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 …
Over the last 12 months, insiders at Taysha Gene Therapies, Inc. have bought $0 and sold $6.66M worth of Taysha Gene Therapies, Inc. stock.
On average, over the past 5 years, insiders at Taysha Gene Therapies, Inc. have bought $6.68M and sold $2.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750,000 shares for transaction amount of $2.06M was made by Manning Paul B (10 percent owner) on 2025‑05‑30.
| 2026-07-10 | Sale | Nagendran Sukumar | President and Head of R&D | 200,000 0.0759% | $6.24 | $1.25M | -15.14% | |
| 2026-04-10 | Sale | Nagendran Sukumar | President and Head of R&D | 200,000 0.077% | $4.46 | $892,000 | +28.06% | |
| 2026-02-04 | Sale | Alam Kamran | CHIEF FINANCIAL OFFICER | 1,655 0.0007% | $4.52 | $7,481 | +20.48% | |
| 2026-01-26 | Sale | Nolan Sean P. | Chief Executive Officer | 41,312 0.0169% | $4.61 | $190,448 | +14.41% | |
| 2026-01-26 | Sale | Alam Kamran | CHIEF FINANCIAL OFFICER | 23,849 0.0098% | $4.61 | $109,944 | +14.41% | |
| 2026-01-26 | Sale | Nagendran Sukumar | President and Head of R&D | 26,918 0.011% | $4.61 | $124,092 | +14.41% | |
| 2026-01-23 | Sale | Nolan Sean P. | Chief Executive Officer | 136,789 0.0585% | $4.75 | $649,748 | +15.67% | |
| 2026-01-23 | Sale | Alam Kamran | CHIEF FINANCIAL OFFICER | 78,968 0.0337% | $4.75 | $375,098 | +15.67% | |
| 2026-01-23 | Sale | Nagendran Sukumar | President and Head of R&D | 89,132 0.0381% | $4.75 | $423,377 | +15.67% | |
| 2026-01-12 | Sale | Nagendran Sukumar | President and Head of R&D | 200,000 0.0741% | $4.71 | $942,000 | +6.48% | |
| 2025-12-01 | Sale | Nagendran Sukumar | President and Head of R&D | 260,047 0.1012% | $4.51 | $1.17M | +20.77% | |
| 2025-11-28 | Sale | Nagendran Sukumar | President and Head of R&D | 110,125 0.0422% | $4.75 | $523,094 | +12.66% | |
| 2025-09-10 | Sale | Nagendran Sukumar | President and Head of R&D | 200,000 0.0837% | $3.23 | $646,000 | +58.46% | |
| 2025-08-21 | Sale | Alam Kamran | CHIEF FINANCIAL OFFICER | 54,491 0.0228% | $2.85 | $155,299 | +72.82% | |
| 2025-08-21 | Sale | Nagendran Sukumar | President and Head of R&D | 57,054 0.0239% | $2.85 | $162,604 | +72.82% | |
| 2025-05-30 | Manning Paul B | 10 percent owner | 750,000 0.3545% | $2.75 | $2.06M | +67.16% | ||
| 2024-06-27 | Manning Paul B | 10 percent owner | 1.33M 0.7863% | $2.25 | $3M | -6.45% | ||
| 2023-11-17 | Manning Paul B | 10 percent owner | 100,000 0.0519% | $1.63 | $163,000 | +27.65% | ||
| 2023-08-24 | Sale | Alam Kamran | Chief Financial Officer | 33,000 0.0537% | $2.33 | $76,890 | -1.71% | |
| 2023-08-16 | Manning Paul B | 10 percent owner | 16.47M 11.9647% | $0.90 | $14.82M | +19.17% |
| Nolan Sean P. | Chief Executive Officer | 2908257 0.8952% | $11.89M | 2 | 2 | <0.0001% |
| Nagendran Sukumar | President and Head of R&D | 936410 0.2882% | $3.83M | 2 | 9 | <0.0001% |
| Session R.A. II | 10 percent owner | 8871747 2.7309% | $36.29M | 1 | 6 | <0.0001% |
| Manning Paul B | 10 percent owner | 2841704 0.8747% | $11.62M | 10 | 0 | <0.0001% |
| Stalfort John A III | director | 999381 0.3076% | $4.09M | 1 | 0 | +19.17% |
| Donenberg Phillip B. | director | 114111 0.0351% | $466,713.99 | 2 | 0 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$831,902,292 | 108 | 9.34% | $1.2B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B |
| Increased Positions | 126 | +75.9% | 43M | +16.15% |
| Decreased Positions | 72 | -43.37% | 34M | -13.02% |
| New Positions | 64 | New | 16M | New |
| Sold Out Positions | 23 | Sold Out | 6M | Sold Out |
| Total Postitions | 220 | +32.53% | 273M | +3.13% |
| Rtw Investments, Lp | $127,860.00 | 8.89% | 24.35M | -667,293 | -2.67% | 2025-09-30 |
| Ra Capital Management, L.P. | $123,667.00 | 8.6% | 23.56M | 0 | 0% | 2025-09-30 |
| Avoro Capital Advisors Llc | $113,925.00 | 7.92% | 21.7M | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $101,365.00 | 7.05% | 19.31M | +2M | +14.48% | 2025-09-30 |
| Blackrock, Inc. | $85,916.00 | 5.97% | 16.36M | +3M | +23.01% | 2025-09-30 |
| Fmr Llc | $76,615.00 | 5.33% | 14.59M | -1M | -6.62% | 2025-09-30 |
| Goldman Sachs Group Inc | $70,264.00 | 4.89% | 13.38M | +796,008 | +6.32% | 2025-09-30 |
| Vanguard Group Inc | $67,460.00 | 4.69% | 12.85M | +2M | +17.95% | 2025-09-30 |
| Siren, L.L.C. | $57,827.00 | 4.02% | 11.01M | 0 | 0% | 2025-09-30 |
| Octagon Capital Advisors Lp | $47,604.00 | 3.31% | 9.07M | -4M | -27.99% | 2025-09-30 |